China advisory committee to review CASI's multiple myeloma therapy

CASI Pharmaceuticals Inc. (NASDAQ:CASI) said China's Expert Advisory Anti-Tumor (Oncology) Drugs Committee will meet to review an application for CASI's Evomela melphalan to treat multiple myeloma. China FDA's Center for Drug Evaluation told CASI the review is scheduled for April 25-26.

Evomela is under Priority Review in China. CASI said the advisory committee was expected as part of recently implemented CFDA reforms...